The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s ...

MapLight Therapeutics, the second biotech to launch a Nasdaq bid this month, is a neuro-focused company advancing treatments ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...

In an interview with German-language outlet Neue Zuercher Zeitung, Novartis CEO Vas Narasimhan said the company is exploring ...

The acquisition of breakout obesity star Metsera should pump new life into Pfizer's portfolio, which over the last two years ...

With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space ...

Building and scaling biopharma workforces can go beyond recruiting permanent employees to include fractional workers and ...

The FDA’s proposed Rare Disease Evidence Principles review process is a starting point for getting rare disease therapies ...

Bluebird bio has re-emerged after a private equity buyout as Genetix Biotherapeutics, marking a return to its roots and a new ...

BMO Capital Markets analysts said the first day of the CDC vaccine advisory committee meeting Thursday had anti-vaccine ...

Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected ...

This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck ...